Integra LifeSciences Holdings (IART)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.12B
Last updated: Nov 17, 2026 at 11:06 AM ET
Integra LifeSciences Holdings (IART) Earnings: Report Dates and Results
Integra LifeSciences Holdings (IART) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Integra LifeSciences Holdings reported EPS of $0.59, above the $0.56 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
IART has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 18.1% below the $0.83 reported for the quarter ended Dec 31, 2025.
IART Earnings Call
The latest IART earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, IART beat 29, missed 5 and matched 6. Revenue for the quarter ended Sep 30, 2026 was $411.18M, up 2.3% from $402.06M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.59 | $0.56 | $0.55 - $0.57 | +5.36% | Beat | +9.3% | 10 | 1 up, 2 down | Oct 21, 2026 | $411.18M |
| Jun 30, 2026 | $0.56 | $0.48 | $0.45 - $0.50 | +16.67% | Beat | +24.4% | 11 | 1 up, 5 down | Jul 29, 2026 | $418.76M |
| Mar 31, 2026 | $0.54 | $0.40 | $0.40 - $0.41 | +35.00% | Beat | +31.7% | 7 | 0 up, 7 down | May 5, 2026 | $391.92M |
| Dec 31, 2025 | $0.83 | $0.79 | $0.78 - $0.82 | +5.06% | Beat | -14.4% | 9 | 0 up, 1 down | Feb 26, 2026 | $434.93M |
| Sep 30, 2025 | $0.54 | $0.43 | $0.42 - $0.45 | +25.58% | Beat | +31.7% | 10 | 0 up, 9 down | Oct 30, 2025 | $402.06M |
| Jun 30, 2025 | $0.45 | $0.43 | $0.42 - $0.46 | +4.65% | Beat | -28.6% | 10 | 0 up, 10 down | Jul 31, 2025 | $415.61M |
| Mar 31, 2025 | $0.41 | $0.43 | $0.41 - $0.45 | -4.65% | Miss | -25.5% | 10 | 0 up, 7 down | May 5, 2025 | $382.65M |
| Dec 31, 2024 | $0.97 | $0.86 | $0.83 - $0.87 | +13.40% | Beat | +9.0% | 10 | 0 up, 1 down | Feb 25, 2025 | $442.65M |
| Sep 30, 2024 | $0.41 | $0.39 | $0.35 - $0.42 | +5.13% | Beat | -46.1% | 12 | 0 up, 0 down | Nov 4, 2024 | $380.83M |
| Jun 30, 2024 | $0.63 | $0.62 | $0.60 - $0.64 | +1.61% | Beat | -11.3% | 11 | 0 up, 0 down | Jul 29, 2024 | $418.18M |
| Mar 31, 2024 | $0.55 | $0.55 | $0.53 - $0.58 | 0.00% | In line | -25.7% | 12 | 0 up, 0 down | May 6, 2024 | $368.87M |
| Dec 31, 2023 | $0.89 | $0.90 | $0.89 - $0.92 | -1.11% | Miss | -5.3% | 11 | 0 up, 0 down | Feb 28, 2024 | $397.04M |
| Sep 30, 2023 | $0.76 | $0.78 | $0.76 - $0.79 | -2.56% | Miss | -11.6% | 11 | 1 up, 0 down | Oct 25, 2023 | $382.42M |
| Jun 30, 2023 | $0.71 | $0.57 | $0.56 - $0.59 | +24.56% | Beat | -13.4% | 11 | 0 up, 1 down | Jul 26, 2023 | $381.27M |
| Mar 31, 2023 | $0.74 | $0.74 | $0.72 - $0.75 | 0.00% | In line | 0.0% | 11 | 0 up, 0 down | Apr 26, 2023 | $380.85M |
| Dec 31, 2022 | $0.94 | $0.90 | $0.89 - $0.94 | +4.44% | Beat | +11.9% | 12 | 2 up, 0 down | Feb 22, 2023 | $398.02M |
| Sep 30, 2022 | $0.86 | $0.72 | $0.69 - $0.80 | +19.44% | Beat | 0.0% | 11 | 0 up, 3 down | Oct 26, 2022 | $385.19M |
| Jun 30, 2022 | $0.82 | $0.80 | $0.79 - $0.81 | +2.50% | Beat | +3.8% | 10 | 0 up, 1 down | Jul 27, 2022 | $397.81M |
| Mar 31, 2022 | $0.74 | $0.68 | $0.65 - $0.69 | +8.82% | Beat | +7.2% | 12 | 0 up, 0 down | Apr 27, 2022 | $376.64M |
| Dec 31, 2021 | $0.84 | $0.83 | $0.81 - $0.85 | +1.20% | Beat | 0.0% | 13 | 1 up, 0 down | Feb 23, 2022 | $405.52M |
| Sep 30, 2021 | $0.86 | $0.72 | $0.71 - $0.75 | +19.44% | Beat | +7.5% | 13 | 0 up, 0 down | Nov 2, 2021 | $386.86M |
| Jun 30, 2021 | $0.79 | $0.66 | $0.65 - $0.69 | +19.70% | Beat | +139.4% | 13 | N/A | Jul 28, 2021 | $389.99M |
| Mar 31, 2021 | $0.69 | $0.57 | $0.56 - $0.58 | +21.05% | Beat | +43.7% | 13 | N/A | Apr 28, 2021 | $360.07M |
| Dec 31, 2020 | $0.84 | $0.73 | $0.69 - $0.87 | +15.07% | Beat | +23.5% | 13 | N/A | Feb 18, 2021 | $388.65M |
| Sep 30, 2020 | $0.80 | $0.54 | $0.44 - $0.59 | +48.15% | Beat | +17.6% | 13 | N/A | Oct 28, 2020 | $370.23M |
| Jun 30, 2020 | $0.33 | $0.15 | -$0.02 - $0.24 | +120.00% | Beat | -54.8% | 12 | N/A | Aug 10, 2020 | $258.67M |
| Mar 31, 2020 | $0.48 | $0.63 | $0.55 - $0.69 | -23.81% | Miss | -26.2% | 10 | N/A | May 7, 2020 | $354.32M |
| Dec 31, 2019 | $0.68 | $0.67 | $0.64 - $0.68 | +1.49% | Beat | +4.6% | 12 | N/A | Feb 19, 2020 | $395.13M |
| Sep 30, 2019 | $0.68 | $0.66 | $0.64 - $0.71 | +3.03% | Beat | +15.3% | 13 | N/A | Oct 24, 2019 | $379.10M |
| Jun 30, 2019 | $0.73 | $0.66 | $0.64 - $0.68 | +10.61% | Beat | +21.7% | 14 | N/A | Jul 24, 2019 | $383.64M |
| Mar 31, 2019 | $0.65 | $0.61 | $0.59 - $0.63 | +6.56% | Beat | +12.1% | 16 | N/A | Apr 24, 2019 | $359.69M |
| Dec 31, 2018 | $0.65 | $0.62 | $0.59 - $0.64 | +4.84% | Beat | +1.6% | 16 | N/A | Feb 21, 2019 | $383.31M |
| Sep 30, 2018 | $0.59 | $0.59 | $0.58 - $0.60 | 0.00% | In line | +31.1% | 13 | N/A | Oct 31, 2018 | $365.85M |
| Jun 30, 2018 | $0.60 | $0.60 | $0.58 - $0.61 | 0.00% | In line | +33.3% | 14 | N/A | Jul 25, 2018 | $366.19M |
| Mar 31, 2018 | $0.58 | $0.49 | $0.48 - $0.51 | +18.37% | Beat | +48.7% | 14 | N/A | Apr 25, 2018 | $357.08M |
| Dec 31, 2017 | $0.64 | $0.56 | $0.54 - $0.58 | +14.29% | Beat | +23.1% | 14 | N/A | Feb 27, 2018 | $368.60M |
| Sep 30, 2017 | $0.45 | $0.47 | $0.46 - $0.50 | -4.26% | Miss | -4.3% | 14 | N/A | Oct 26, 2017 | $278.83M |
| Jun 30, 2017 | $0.45 | $0.45 | $0.43 - $0.48 | 0.00% | In line | +12.5% | 15 | N/A | Jul 26, 2017 | $282.16M |
| Mar 31, 2017 | $0.39 | $0.38 | N/A | +2.63% | Beat | +5.4% | N/A | N/A | Apr 26, 2017 | $258.64M |
| Dec 31, 2016 | $0.52 | $0.52 | N/A | 0.00% | In line | +18.2% | N/A | N/A | Feb 23, 2017 | $255.66M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $2.23, down 12.9% from the year before. It was $1.76 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $2.23 | -12.9% |
| Dec 31, 2024 | $2.56 | -17.4% |
| Dec 31, 2023 | $3.10 | -7.7% |
| Dec 31, 2022 | $3.36 | +5.7% |
| Dec 31, 2021 | $3.18 | +29.8% |
| Dec 31, 2020 | $2.45 | -10.6% |
| Dec 31, 2019 | $2.74 | +13.2% |
| Dec 31, 2018 | $2.42 | +25.4% |
| Dec 31, 2017 | $1.93 | +9.7% |
| Dec 31, 2016 | $1.76 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,900 words across 13 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,903 | 13 | |
| 2026Q2 | Jun 30, 2026 | 5,516 | 11 | |
| 2026Q1 | Mar 31, 2026 | 7,415 | 12 | |
| 2025Q4 | Dec 31, 2025 | 4,577 | 7 | |
| 2025Q3 | Sep 30, 2025 | 5,418 | 9 | |
| 2025Q2 | Jun 30, 2025 | 5,555 | 9 | |
| 2025Q1 | Mar 31, 2025 | 6,883 | 12 | |
| 2024Q4 | Dec 31, 2024 | 7,081 | 13 |
2026Q3 Earnings Call
Opening remarks
Chris Ward Senior Director, Investor Relations Good morning, and thank you for joining the Integra LifeSciences third quarter 2026 earnings conference call. Joining me on the call are Stuart Essig, Chairman and Chief Executive Officer, and Lea Knight, Chief Financial Officer. We issued a press release this morning announcing our third quarter 2026 financial results. The release and earnings presentation we reference during the call are available at integralife.com under Investors, Events and Presentations in a file named Third Quarter 2026 Earnings Presentation. Before we begin, I want to remind you that many statements made during this call may be considered forward-looking. Factors that could cause actual results to differ materially are discussed in the company's Exchange Act reports that we filed with the SEC. These factors are also detailed in the release. Also, in our prepared remarks, we will reference reported and organic revenue growth. Organic revenue growth excludes the effects of foreign currency, acquisitions, and divestitures. Unless otherwise stated, all disaggregated and franchise-level revenue growth rates are based on organic performance. Lastly, our comments today will include certain non-GAAP financial measures. Reconciliations of non-GAAP financial measures are included in today's press release, which is an exhibit to Integra's current report on Form 8-K filed today with the SEC. With that, I will now turn the call over to Stuart.
Stuart Essig Chairman and CEO Good morning, everyone, and thank you for joining us. As many of you know, we provided preliminary third quarter 2026 financial results and an updated full-year 2026 outlook on October 2 in conjunction with the initiation of our refinancing. We recognize that the update was disappointing, particularly because it came against a backdrop of meaningful progress for the company during the year. Today, I want to provide more context on our third quarter performance, the factors that shaped our updated outlook, and our priorities as we look ahead to 2027. For the third quarter, we delivered revenue of $411 million, which was at the low end of our guidance range. During the quarter, the Cincinnati disruption proved more significant than initially expected, and growth in Tissue Reconstruction did not materialize as anticipated. At the same time, upside in neurosurgery offset much of those headwinds. We delivered adjusted earnings per share of $0.59 and generated $96 million of operating cash flow. We also reduced leverage to 3.8 times, and subsequent to the end of the quarter, we successfully completed a debt refinancing. The quarter's strong cash generation, lower leverage, and successful refinancing have strengthened our balance sheet and increased our financial flexibility. Together, these are important indicators of the progress we are making to improve Integra's overall financial profile and support continued execution of our priorities.
Frequently Asked Questions About IART
When is Integra LifeSciences Holdings's next earnings date?
Integra LifeSciences Holdings's next earnings report is expected for Feb 24, 2027.
Did IART beat earnings estimates last quarter?
Yes. Integra LifeSciences Holdings reported EPS of $0.59 for the quarter ended Sep 30, 2026, above the $0.56 estimate, a 5.36% surprise.
What EPS do analysts expect from IART next quarter?
The consensus EPS estimate for Integra LifeSciences Holdings for the quarter ending Dec 31, 2026 is $0.68 from 13 analysts, with estimates from $0.61 to $0.88.
How often does IART beat earnings estimates?
Integra LifeSciences Holdings beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +12.63%.
IART pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors